Dr. Xingli Wang

It's almost like screening.

And at the moment, we for sure will go to phase three as an asthma cell lung cancer.

And back to your question, you have two concerns.

Obviously, one is other tissues, some of other tissues also express PD-L1s.

So this has had to be carefully titrated in relation to the dosing.

And, you know, for most of the current immunotherapies, you always come across that type of risk.

That's why sometimes you think about it, is ADC going to solve the problem?

Probably will not.

You can have the T-cell engager, double antibodies, might have a better profile eventually.

And also, even with PD-L1 inhibitor ADCs, you're hoping it not only kills PD-L1 cancer cells, expression cancer cells, also the neighbors, the ones bystanders.

but that do not, or PD-L1 low.

And it's interesting, as you said, PD-L1, you block it to make sure it does its active T cells towards cancer cells, and you don't get muted by the PD-L1.

But it's the same thing.

It's only about 40% to around 40% to 50% of patients

responding to PD-L1, so which clearly indicate, you know, some of the solid tumors is not really expressing, all cells expressing the PD-L1, and even you kill these expressing ones, you're still going to be like PD-L1 negative cancer cells get, you know, becoming dominant.

So these are still the issue to be resolved.

The PD-L1 or the 43 will be major breakthrough, but it's certainly not to be the end of story to resolve all the issues.

But we do feel this ADC

Again, Sam, it's bad for us, as a scientist, to say that sometimes you design a drug and you're also playing a bit on the luck.

As an ADC, you're looking at which DAR will give you the best outcome, the balance of risk and benefit.